Verizon Communications (TG:BACL)
Historical Stock Chart
From Jul 2019 to Jul 2024
Expert Panel to Discuss Growing Global Impact and Innovative New
Solutions to Emerging Diseases
Breakfast Sponsored by Bioaccelerate Holdings Inc. to be Held at Milken
Institute Global Conference
NEW YORK, April 11 /PRNewswire-FirstCall/ -- Bioaccelerate Holdings Inc.
(OTC:BACL) (BULLETIN BOARD: BACL) announced today a distinguished panel of
experts to discuss the global impact and innovative new solutions to the
treatment of neglected diseases at its Company-sponsored breakfast meeting at
the Milken Institute Global Conference. The invitation-only breakfast will
take place on April 19, 2005, from 6:45 a.m. to 7:45 a.m. in the Brighton Room
in the Executive Center of the Beverly Hilton Hotel in Los Angeles, CA.
"Infectious diseases pose an urgent global crisis-threatening the economic
survival of the poorest countries and the growth and development of many more,"
stated Bruce Murdoch, Acting Chief Executive Officer of Candid Pharmaceuticals,
a Bioaccelerate subsidiary focused on emerging diseases. "Broad-based efforts
by organizations like the World Health Organization (WHO) should be commended
and supported through international effort by governments, academic
institutions and the healthcare industry."
"Since the 1970s, at least 30 new infectious diseases have emerged for which
effective treatments either do not exist or do not always find their ways to
patients. Studies on the effect of AIDS, malaria and tuberculosis indicate that
the social structures and functioning of societies increasingly affected by
these diseases are being systematically eroded," commented Frank Armstrong,
M.D., Chief Operating Officer of Bioaccelerate. "The very concept of
sustainable global economic growth may be at stake. For that reason, this panel
topic strongly echoes other key themes that will be discussed throughout the
conference-health, security, trade and globalization."
The panelists include:
* Greg Simon, President, FasterCures / The Center for Accelerating
Medical Solutions
Mr. Simon will moderate this breakfast panel, highlighting the urgent
need for a more focused US and international policy and action plan
for dealing with the dire economic impact and immeasurable human toll
from the uncontrolled spread of deadly infectious diseases. Mr. Simon
will discuss how, increasingly, epidemics such as SARS have emerged as
one of greatest risk factors threatening the stability of an
interdependent international economic community and how global
companies need to address this threat within their strategic business
decisions.
Prior to joining FasterCures in July 2003, Mr. Simon was CEO of Simon
Strategies/Mindbeam, a consulting firm focusing on clients in
biotechnology, health care, technology and information technology
among other issues. From 1993 to 1997, he was Chief Domestic Policy
Advisor to Vice President Al Gore specifically on economic, science
and technology issues. In that capacity, he oversaw a number of
initiatives, including the programs of the National Institutes of
Health, National Cancer Institute, Food and Drug Administration (FDA),
the Human Genome Project, and the development of the regulatory
framework for biotechnology products.
* Michael J. Ryan, MD, MPH, MFPHM, Coordinator of WHO's Global Alert and
Response Unit
Dr. Ryan will provide a "view from the front line" in fighting
emerging diseases. His remarks will focus on how the WHO is working
with partners to put into place an effective global alert and response
system, the need for an investment in building national capacities to
detect and respond to these threats and what the private sector can do
it terms of product development and corporate support. This
presentation will draw deeply from his experiences in dealing with
over 50 international responses over the past three years.
Dr. Ryan has worked with WHO since 1996, when WHO established a unit
to respond to emerging and epidemic disease threats. During his time
at WHO, Dr. Ryan has led numerous outbreak response teams to the field
for diseases such as Ebola, meningitis, cholera, bacillary dysentery,
Crimean-Congo hemorrhagic fever, rift valley fever and relapsing
fever. He became Coordinator of WHO's Global Alert and Response Team
in 2001 and has put into place WHO's epidemic intelligence,
verification and response mechanisms, as well as the Global Outbreak
Alert and Response Network (GOARN), which have been utilized in recent
outbreaks such as SARS and Influenza. He was appointed Director of
Alert and Response Operations in June 2004 with responsibility for the
further development and implementation of the WHO-wide response to
epidemics and other public health emergencies of international concern
requiring immediate operational response and has WHO's Strategic
Health Operations Centre under his responsibility. He completed
Medical Training at University College Galway and his Masters in
Public Health at University College Dublin followed by specialist
training in public health/communicable disease at the UK Communicable
Disease Surveillance Centre in London.
* Frank Armstrong, M.D., Chief Operating Officer, Bioaccelerate
Dr. Armstrong will discuss how Bioaccelerate's business model helps
streamline the process of developing a drugs for a variety of
diseases, including infectious diseases, and bringing needed
treatments to millions of people worldwide.
Dr. Armstrong joined Bioaccelerate in January 2005. Previously, he was
CEO of Provensis, a BTG Company, and CEO of Phoqus, a private drug
delivery company. Earlier, he was Head of Worldwide Product
Development for Bayer AG, and Senior Vice President Medical Research
and Communications Group, Zeneca Pharmaceuticals (now AstraZeneca),
based in the US. Dr. Armstrong holds degrees from the University of
Edinburgh in Biochemistry and Medicine and is a Fellow of the Royal
College of Physicians (Edinburgh) and a Fellow of the Faculty of
Pharmaceutical Medicine in the UK.
ABOUT THE WORLD HEALTH ORGANIZATION
The WHO is the United Nations specialized agency for health. It was established
on 7 April 1948. WHO's objective, as set out in its Constitution, is the
attainment by all peoples of the highest possible level of health. Health is
defined in WHO's Constitution as a state of complete physical, mental and
social well being and not merely the absence of disease or infirmity.
Additional information on The World Health Organization is available at
http://www.who.org/.
ABOUT FASTERCURES / THE CENTER FOR ACCELERATING MEDICAL SOLUTIONS
FasterCures is an "action tank" committed to building faster tracks to find
tomorrow's cures today. Its mission is to clear the path between an idea for
treatment and getting a treatment to the patient. Additional information is
available at http://www.fastercures.org/.
ABOUT THE MILKEN INSTITUTE GLOBAL CONFERENCE
This year's conference, "Building a Prosperous Future," will examine such
issues as biotechnology and the promise of medical breakthroughs; the global
investment climate; and the latest economic developments in Europe, Asia, Latin
America and the US.
Among confirmed speakers at the conference are former Vice President Al Gore;
Rupert Murdoch, Chairman and CEO, News Corporation; Terry Semel, Chairman and
CEO, Yahoo!; Charlene Barshefsky, former U.S. Trade Representative; Mel
Karmazin, CEO, SIRIUS Satellite Radio; Steve Forbes, President and CEO, Forbes;
William Haseltine, former CEO, Human Genome Sciences; Jonathan Miller, Chairman
and CEO, AOL; Mike Milken, Chairman of FasterCures and the Milken Institute;
Steve Wynn, President and CEO, Wynn Resorts; Sam Zell, Chairman, Equity Group
Investments; and more than 300 others.
For complete information about the 2005 Global Conference, go to:
http://www.milkeninstitute.org/gc2005.
ABOUT BIOACCELERATE HOLDINGS INC.
Bioaccelerate Holdings Inc. (BACL.OB) is a pharmaceutical development
organization ("PDO"). It conducts its business directly and through its
subsidiaries. The company holds majority equity interests in 10
biopharmaceutical companies, three of which are public, and holds minority
interests in four biopharmaceutical companies, two of which are public. The
company also holds a minority equity interest in a public nanotechnology
company. Bioaccelerate's strategy relies on its development network for
research, clinical development and project management to guide early-stage
compounds from the discovery process through to Phase II/III development where
incremental value can be created. Bioaccelerate Holdings is listed on the
Over-The-Counter Bulletin Board under the symbol "BACL.OB." For more
information on Bioaccelerate, visit the Company's website at
http://www.bioaccelerate.com/.
CONTACT:
Bioaccelerate Holdings Inc.
Christopher O'Toole
Senior Vice President
212-332-4387
Matthew Haines (Investors)
Vice President
Noonan Russo
212-845-4235
Emily Poe (Media)
Vice President
Noonan Russo
212-845-4266
DATASOURCE: Bioaccelerate Holdings Inc.
CONTACT: Christopher O'Toole, Senior Vice President of Bioaccelerate
Holdings Inc., +1-212-332-4387; or Matthew Haines (Investors), Vice President
of Noonan Russo, +1-212-845-4235; or Emily Poe (Media), Vice President of
Noonan Russo, +1-212-845-4266
Web site: http://www.bioaccelerate.com/